BridgeBio Oncology Therapeutics, Inc. (BBOT)
NGM – Real Time Price. Currency in USD
8.88
-0.35 (-3.79%)
At close: Mar 27, 2026, 4:00 PM EDT
8.99
+0.11 (1.24%)
After-hours: Mar 27, 2026, 5:07 PM EDT

NGM – Real Time Price. Currency in USD
8.88
-0.35 (-3.79%)
At close: Mar 27, 2026, 4:00 PM EDT
8.99
+0.11 (1.24%)
After-hours: Mar 27, 2026, 5:07 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 12.34 | 6.05 | 10 | |
| Quick ratio | 12.34 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | -208K | -610K | -610K |
| Operating Income | -4K | -42K | -81M | -146M | -96M |
| Net Income | -4K | -42K | -74M | -134M | -83M |
| EBITDA | -4K | -42K | -81M | -145M | -96M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 99 | 5.5 |
| Next quarter | N/A | 98.92 | 5.5 |
| Current year | N/A | 49.25 | 5.5 |
| Next year | N/A | 0.01 | 1.5 |
| Weighted average score | 4.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 13.32 | 52.43 | 40.55 | 9.5 |
| Y/Y | 999 | -97.06 | N/A | -181.19 | 3.3 |
| 3y average | 999 | -59738.84 | N/A | 630.04 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 4.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $373.7M significantly exceed its total debt $2.8M, ensuring strong financial flexibility
Total current assets $432.4M exceed Total current liabilities $35.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$42.3M limits the company's ability to reinvest or pay down debt